Clinical Trial Update: Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating ferric derisomaltose/iron isomaltoside for recovery in gynecologic oncology ERAS programs; results not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer
• Iron Deficiency Anemia
• Surgery

Drugs mentioned

• Ferric derisomaltose (ferric derisomaltose)
• Iron isomaltoside (iron isomaltoside)

Snippet

Sponsor: Alberta Health Services, Calgary | Conditions: Gynecologic Cancer, Anemia, Iron Deficiency | Phase 3 | Status: UNKNOWN